Literature DB >> 21274876

Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis.

Sara Montagnese1, Anna Biancardi, Sami Schiff, Paolo Carraro, Vincenzo Carlà, Guido Mannaioni, Flavio Moroni, Natascia Tono, Paolo Angeli, Angelo Gatta, Piero Amodio.   

Abstract

UNLABELLED: The diagnosis of hepatic encephalopathy (HE) relies on clinical, neurophysiological, psychometric and laboratory variables. The relationships between such tests remain debated. The aim of this study was to determine the laboratory correlates/prognostic value of neurophysiological/psychometric abnormalities in patients with cirrhosis. Seventy-two patients and 14 healthy volunteers underwent EEG and paper-and-pencil psychometry (PHES). Blood was obtained for C reactive protein (CRP), interleukin 6 (IL6), tumor necrosis factor (TNF)α, ammonia and indole/oxindole. Patients were followed prospectively for a median of 22 months in relation to the occurrence of death, transplantation and HE-related hospitalizations. Thirty-three patients had normal PHES and EEG, 6 had abnormal PHES, 18 abnormal EEG and 13 abnormal PHES and EEG. Patients with abnormal PHES had higher CRP (17 ± 22 vs 7 ± 6, P < 0.01), IL6 (32 ± 54 vs 12 ± 13, P < 0.05) and TNFα (17 ± 8 vs 11 ± 7, P < 0.001) levels than those with normal PHES. Patients with abnormal EEG had higher indole (430 ± 270 vs 258 ± 255, P < 0.01) and ammonia (66 ± 35 vs 45 ± 27, P < 0.05) levels than those with normal EEG. Psychometric test scores showed significant correlations with CRP, TNFα and IL6; EEG indices with ammonia and IL6. CRP and TNFα concentrations were independent predictors of abnormal PHES, ammonia and indole of abnormal EEG on multivariate analysis. Seven patients were lost to follow-up; of the remaining 65, 20 died and 14 underwent transplantation; 15 developed HE requiring hospitalization. PHES and EEG performance were independent predictors of HE and death (P < 0.05).
CONCLUSION: PHES and EEG abnormalities in patients with cirrhosis have partially different biochemical correlates and independently predict outcome.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21274876     DOI: 10.1002/hep.24043

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

Review 2.  Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Authors:  Ming Luo; Ping Ma; Lei Li; Wu-Kui Cao
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

3.  Factors contributing to the development of overt encephalopathy in liver cirrhosis patients.

Authors:  Motoh Iwasa; Ryosuke Sugimoto; Rumi Mifuji-Moroka; Nagisa Hara; Kyoko Yoshikawa; Hideaki Tanaka; Akiko Eguchi; Norihiko Yamamoto; Kazushi Sugimoto; Yoshinao Kobayashi; Hiroshi Hasegawa; Yoshiyuki Takei
Journal:  Metab Brain Dis       Date:  2016-06-29       Impact factor: 3.584

Review 4.  Diagnosis of minimal hepatic encephalopathy.

Authors:  Karin Weissenborn
Journal:  J Clin Exp Hepatol       Date:  2014-07-31

5.  Covert hepatic encephalopathy: agreement and predictive validity of different indices.

Authors:  Sara Montagnese; Esmeralda Balistreri; Sami Schiff; Michele De Rui; Paolo Angeli; Giacomo Zanus; Umberto Cillo; Giancarlo Bombonato; Massimo Bolognesi; David Sacerdoti; Angelo Gatta; Carlo Merkel; Piero Amodio
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 6.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

7.  Effects of common chronic medical conditions on psychometric tests used to diagnose minimal hepatic encephalopathy.

Authors:  M M Lauridsen; L Poulsen; C K Rasmussen; M Høgild; M K Nielsen; O B Schaffalitzky de Muckadell; H Vilstrup
Journal:  Metab Brain Dis       Date:  2015-10-05       Impact factor: 3.584

8.  Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.

Authors:  Maria Garrido; Jelena Skorucak; Daniela Raduazzo; Matteo Turco; Giuseppe Spinelli; Paolo Angeli; Piero Amodio; Peter Achermann; Sara Montagnese
Journal:  Metab Brain Dis       Date:  2016-05-19       Impact factor: 3.584

9.  Diagnosis of covert hepatic encephalopathy without specialized tests.

Authors:  Eiman Nabi; Leroy R Thacker; James B Wade; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Douglas M Heuman; Iliana Bouneva; Arun J Sanyal; Mohammad S Siddiqui; Velimir Luketic; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel Unser; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

10.  Covert hepatic encephalopathy: does the mini-mental state examination help?

Authors:  Michela Corrias; Matteo Turco; Michele D Rui; Angelo Gatta; Paolo Angeli; Carlo Merkel; Piero Amodio; Sami Schiff; Sara Montagnese
Journal:  J Clin Exp Hepatol       Date:  2014-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.